Personalized medicine is continuing to take hold, according to the first-ever annual report from the National Cancer Database (NCDB) of the American College of Surgeons (ACS) Cancer Programs. Among the key findings was that more cancers are being treated with targeted medical therapies before surgery. The report also describes in-depth…

A new type of CRISPR gene editing that targets noncoding RNAs has revealed the important cellular functions that they perform and could help in the development of personalized cancer treatments. Unlike traditional CRISPR which uses the Cas9 enzyme as molecular scissors to cut DNA, the new technology deploys the Cas13…

Data from a team of Australian researchers shows the potential of a new therapeutic strategy for treating castration-resistant prostate cancer (CRPC), the most aggressive form of the disease. The research, published in the British Journal of Cancer, studied the role of Cyclin-Dependent Kinase 9 (CDK9) in the progression of aggressive…

New research from the Brigham and Women’s Hospital investigators has provided new details on different levels of cardiac risks for patient who receive radiation therapy to treat non-small cell lung cancer (NSCLC). The study, published in JACC: CardioOncology, leveraged artificial intelligence (AI) to uncover how different radiation doses impact specific…

Taxanes are often used as chemotherapy for breast cancer, but they can cause side effects in the nervous system, such as foot pain. Researchers at Linköping University in Sweden have now developed a statistical tool that uses sequencing and other data to predict individual risk level for such side effects.…

As a graduate student at the Hebrew University’s Interdisciplinary Center for Neuronal Computation in the late 1990s, Tuvik Beker, PhD, applied his mathematics and machine learning training to investigate the use of artificial neural networks to solve complex problems. Twenty years later, after a long and winding road of applying…

Targeted treatment for non-small cell lung cancer (NSCLC) sometimes fails to work, even in patients who have never smoked. The reason, new research suggests, hangs on two mutations in the EGFR and TP53 genes. Patients with mutations in these two genes are more likely to have mixed intra-patient tumor responses…

UNC Lineberger Comprehensive Cancer Center researchers and colleagues, via two separate articles “Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers,” and “Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancer,” published today in Science, say they have developed the most comprehensive molecular portrait of the oncogene KRAS and how its activities…

A team of researchers led by Kim Eunjung, PhD, at the Natural Products Informatics Research Center of the Korea Institute of Science and Technology (KIST) has developed a mathematical model that provides a theoretical foundation to predict tumor evolution that could provide a method of providing more effective adaptive cancer…

Researchers at Florida International University and First Ascent Biomedical have used an artificial intelligence (AI)-powered, functional precision medicine (FPM) platform to identify unique therapeutic treatment options for children with relapsed cancer diagnoses. They published their study, “Feasibility of Functional Precision Medicine for Guiding Treatment of Relapsed or Refractory Pediatric Cancers,”…

SAN DIEGO—With the exhibition floor about to close on the third day of AACR 2024, most presenters had deserted their posters. But in one of the dozens of rows, several clusters of conversations were happening all around one poster. Several members from Genialis were explaining krasID—an RNA-based biomarker that uses…

A clinical trial led by investigators at The Keck Medicine of USC will investigate the feasibility of providing immunotherapy treatment at home for patients with non-small cell lung cancer (NSCLC). Currently, immunotherapies are only administered intravenously in a doctor’s office or hospital. But the new trial will examine the effectiveness…

A genetic test developed at the University of California San Francisco (UCSF) can identify triple negative breast cancer patients who will and won’t respond to commonly used immunotherapies. Triple negative breast cancer accounts for up to 15% of all breast cancers and affects around 13 in 100,000 women in the…

Scientists have discovered a way to use inhalable exosomes to deliver interleukin-12 (IL-12) mRNA to the lungs for cancer therapy. The technology provides a means of achieving sufficiently concentrated IL-12 levels in the lungs and bypassing some of the off-target side effects of IL-12 therapy delivered systemically through other delivery…

Research led by the University Illinois Chicago shows a common genetic test, used by clinicians to help decide on treatment for women with estrogen receptor (ER) positive breast cancer, is less accurate in Black women. The Oncotype DX 21-gene test creates a recurrence score that is designed to show which…